Roscovitine (Seliciclib, CYC202): Precision CDK2 Inhibitor for Cancer Research

Executive Summary: Roscovitine (Seliciclib, CYC202) is a potent, selective inhibitor of cyclin-dependent kinases (CDKs), targeting CDK2/cyclin E with an IC50 of 0.1 µM, and CDK7, CDK5, and CDC2 with submicromolar potencies [ApexBio]. It arrests eukaryotic cells in late prophase by blocking the prophase/metaphase transition, demonstrated in multiple model organisms (Moret et al., 2019). Roscovitine reduces tumor growth in vivo, as shown in athymic nude mice bearing A4573 tumors. The compound is insoluble in water but highly soluble in DMSO and ethanol, making it suitable for diverse in vitro and in vivo research workflows. Its specificity and well-characterized solubility profile make it a gold-standard research tool for CDK-driven cancer biology.

Biological Rationale

Cyclin-dependent kinases (CDKs) are serine/threonine kinases essential for cell cycle control, transcription, and apoptosis. Deregulation of CDKs, especially CDK2, is implicated in the pathogenesis of many human tumors (Moret et al., 2019). Selective CDK inhibition enables the interrogation of oncogenic cell cycle progression, apoptosis initiation, and the development of targeted therapeutics [See also: Selective CDK2 Inhibitor for Cancer Research]. Roscovitine (Seliciclib, CYC202) provides a precise chemical probe for these processes, delivering high selectivity and minimal off-target effects at recommended concentrations. This article extends prior overviews by providing detailed, up-to-date benchmarks and mechanistic clarifications for translational oncology workflows.

Mechanism of Action of Roscovitine (Seliciclib, CYC202)

Roscovitine is an ATP-competitive, reversible inhibitor of several CDKs, with primary activity against:

• CDK2/cyclin E (IC50 = 0.1 µM)
• CDK7/cyclin H (IC50 = 0.49 µM)
• CDK5/p35 (IC50 = 0.16 µM)
• CDC2/cyclin B (IC50 = 0.65 µM)

At concentrations above 10 µM, Roscovitine also inhibits ERK1 (IC50 = 34 µM) and ERK2 (IC50 = 14 µM), though these activities are significantly weaker than for CDKs [ApexBio product data]. The compound halts the cell cycle at late prophase, specifically blocking the prophase/metaphase transition in a range of eukaryotic models, including Xenopus oocytes and sea urchin embryos. This precise phase arrest enables dissection of checkpoint regulation and mitotic progression, distinguishing Roscovitine from pan-CDK inhibitors [See also: Redefining Translational Oncology].

Evidence & Benchmarks

• Roscovitine inhibits CDK2/cyclin E kinase activity with an IC50 of 0.1 µM in cell-free biochemical assays (ApexBio).
• Cell cycle arrest is observed in late prophase in Xenopus oocytes treated with 50 µM Roscovitine for 2 hours at 20°C (Moret et al., 2019).
• In athymic nude mice bearing A4573 tumors, Roscovitine administered at 100 mg/kg/day IP for 14 days led to significant tumor volume reduction compared to saline controls (Moret et al., 2019).
• ERK1/2 inhibition occurs at higher concentrations (IC50 > 10 µM), with minimal off-target effects at standard working concentrations (ApexBio).
• Roscovitine is insoluble in water but dissolves in DMSO (≥17.72 mg/mL) and ethanol (≥53.5 mg/mL); optimal solubility is achieved by gentle warming and ultrasonic treatment (ApexBio).
• Data-driven library design approaches, such as LSP-OptimalKinase, prioritize selectivity and low off-target overlap for kinase inhibitors including Roscovitine (Moret et al., 2019).

This article clarifies recent mechanistic data and in vivo benchmarks not covered in previous overviews.

Applications, Limits & Misconceptions

Roscovitine is primarily used for:

• Dissecting CDK-dependent cell cycle transitions in cancer biology and developmental models.
• Evaluating CDK2-specific apoptosis induction and checkpoint regulation.
• Benchmarking kinase inhibitor selectivity in cheminformatics-driven library screens (Moret et al., 2019).
• Validating CDK pathway targets in translational oncology workflows ([See also: Precision CDK2 Inhibitor Guide]).

Common Pitfalls or Misconceptions

• Roscovitine is not a pan-CDK inhibitor: It exhibits selectivity for CDK2, CDK7, CDK5, and CDC2, with limited activity toward other kinases at standard concentrations.
• Not suitable for aqueous-only systems: The compound is insoluble in water and requires organic solvents for stock preparation.
• Inhibition of ERK1/2 is weak and only occurs at high concentrations (>10 µM): Use below these levels to avoid off-target MAPK pathway effects.
• Does not substitute for genetic CDK2 knockouts: Chemical inhibition can have distinct cellular effects compared to gene deletion or silencing.
• Long-term storage of solutions is not recommended: Degradation may occur; always prepare fresh solutions for critical experiments.

Workflow Integration & Parameters

Roscovitine (Seliciclib, CYC202) is provided as a solid (SKU: A1723) and should be stored at -20°C. For experimental use, dissolve in DMSO (≥17.72 mg/mL) or ethanol (≥53.5 mg/mL). Warming and ultrasonic treatment can enhance solubility. Avoid repeated freeze-thaw cycles and long-term storage of stock solutions. For cell-based assays, typical working concentrations range from 1–50 µM, depending on cell type and assay duration. In vivo studies in mice have used 100 mg/kg/day administered intraperitoneally for 14 days to achieve tumor suppression [ApexBio]. Always include appropriate solvent controls and monitor for solvent toxicity. For high-throughput kinase screens, Roscovitine can be incorporated into cheminformatics-optimized libraries to maximize selectivity and minimize off-target pharmacology (Moret et al., 2019). This article updates workflow guidance beyond that found in previous mechanistic summaries.

Conclusion & Outlook

Roscovitine (Seliciclib, CYC202) remains a reference-standard tool for probing CDK2-dependent signaling in cancer and cell cycle biology. Its robust IC50 profile, in vivo efficacy, and predictable solubility enable precise and reproducible experimental workflows. Future developments in chemical probe libraries and data-driven selection tools will further enhance its role in translational oncology and systems pharmacology (Moret et al., 2019). For detailed protocols and ordering, see the Roscovitine (Seliciclib, CYC202) product page.